{
    "nctId": "NCT00465725",
    "briefTitle": "A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors",
    "officialTitle": "A Randomized Crossover Oral Bioavailability Study Comparing the Pharmacokinetics and Pharmacodynamics of Picoplatin Administered Orally With Picoplatin Administered Intravenously in Subjects With Advanced Non-Hematological Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "MTD",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological diagnosis of non-hematological malignancy.\n* Patients for whom no standard therapy exists and for whom, in the opinion of the investigator, treatments with single agent picoplatin is appropriate.\n* 18 years of age or older.\n* ECOG performance status 0-2.\n* Life expectancy of at least 12 weeks.\n\n(Additional inclusion criteria apply.)\n\nExclusion Criteria:\n\n* Symptomatic or uncontrolled brain metastases.\n* Prior radiation involving \u2265 30% of the total bone marrow space.\n* Any concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study.\n* Gastrointestinal surgery that might interfere with absorption of orally administered drug.\n* Active inflammatory bowel disease, gastritis, ulcers, gastrointestinal or rectal bleeding.\n* Clinical evidence of pancreatic injury or active pancreatitis.\n* Female subjects who are pregnant or breastfeeding.\n\n(Additional exclusion criteria apply.)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}